Abstract
The guanylate cyclase-C receptor agonist linaclotide (Linzess – Abbvie/Ironwood) was first approved by the FDA in 2012 for treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation in adults.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have